INTRODUCTION
============

Obesity is associated with the development and progression of various cancers such as breast cancer, endometrial cancer, colon cancer, esophageal adenocarcinoma, prostate cancer, liver cell carcinoma, leukemia, non-Hodgkin lymphoma, and melanoma \[[@B1][@B2][@B3][@B4]\]. Recently, several epidemiologic studies have suggested a positive association between obesity and the prevalence of thyroid cancer \[[@B5][@B6][@B7][@B8][@B9][@B10]\].

In addition to the increased prevalence of cancers, obesity is associated with aggressive pathological features and poor clinical outcomes such as increased risk of recurrence and progression in breast and prostate cancers \[[@B11][@B12][@B13][@B14]\]. The relationships between obesity and clinical outcomes of thyroid cancer remain still controversial. Three studies showed a correlation between obesity and more advanced tumor stages \[[@B5][@B15][@B16]\]. A report suggested that overweight or obese patients with papillary thyroid carcinomas (PTC) larger than 1 cm in size had the increased risk of developing loco-regional persistent or recurrent disease \[[@B5]\]. However, other studies reported that a higher body mass index (BMI) was not associated with more aggressive pathological features, or the recurrence or persistence of disease \[[@B17][@B18]\]. In fact, one study suggested that obesity might be correlated with less aggressive tumor invasion, although this finding was not statistically significant \[[@B17]\].

In the present study, we evaluated the associations of an increased BMI with clinicopathological features and the recurrence-free survivals in patients with PTCs equal to or larger than 1 cm in size.

METHODS
=======

Study subjects and design
-------------------------

This retrospective study included 1,189 patients who underwent total thyroidectomy for PTCs equal to or larger than 1 cm in size at Asan Medical Center in Seoul, Korea between 2000 and 2005. We reviewed medical records of the patients including preoperative body weights, heights, surgical records, pathology reports, and the results of therapeutic whole body scans to assess the initial clinicopathological status for each patient. The tumor node metastasis (TNM) stage was based on the seventh edition of the American Joint Committee on Cancer (AJCC) staging manual \[[@B19]\].

Anthropometric measurements
---------------------------

On the day of admission for thyroid surgery, the heights and weights were measured in patients wearing light clothing without shoes. BMI was calculated using the following formula; the weight in kilograms stratified by square of the height in meters (kg/m^2^). For comparisons, patients were stratified into four groups according to gender-specific quartiles for BMI (kg/m^2^): Q1 19.4 to 23.0, Q2 23.1 to 24.9, Q3 25.0 to 26.9, and Q4 27.0 to 38.2 for males; Q1 15.8 to 21.7, Q2 21.8 to 23.5, Q3 23.6 to 25.9, and Q4 26.0 to 37.1 for females.

Follow-up protocol for the detection of clinical recurrence
-----------------------------------------------------------

As we previously described, all patients were subjected to regular physical examinations and assessments of serum thyroglobulin (TG) levels in every 6 to 12 months interval \[[@B20]\]. Neck ultrasonography examinations were performed at least once during the follow-up period. Stimulated TG levels were evaluated in patients with thyroid-stimulating hormone withdrawal approximately 12 months after total thyroidectomy. Additional diagnostic imaging studies including fluorodeoxyglucose positron emission tomography and chest computed tomography scans, were performed in patients whose distant metastases were clinically under suspicions \[[@B20]\]. Clinical recurrence was defined as the reappearance of pathologically proven malignant tissues and/or the appearance of metastatic lesions in the lung, bone, and/or brain in patients initially confirmed to be in remission \[[@B20]\].

Statistical analysis
--------------------

Categorical variables are presented as numbers and percentages. Continuous variables are expressed as mean±standard deviation. The BMI quartiles were calculated separately for males and females. All data analyses were performed using R version 3.0 and R libraries survival (R Foundation for Statistical Computing, Vienna, Austria; <http://www.R-project.org>). The comparisons of continuous variables, such as age and maximal tumor diameter, according to BMI quartiles were conducted using analysis of variance or Student *t* test. Trends across the increases in BMI quartiles were performed using a Cochran-Armitage trend test, except for the nodal metastasis variable. Categorical variables were analyzed using chi-square tests. In the multivariate analyses, the relative associations between BMI quartiles and advanced TNM stage or multifocality were presented as odds ratios (ORs) with 95% confidence intervals (CIs) which were calculated using binominal logistic regression analyses. A log-rank test was used to compare recurrence-free survivals among the BMI quartiles. Hazard ratios (HRs) and 95% CIs were derived from the Cox proportional hazards model. All of *P* values were two-sided. *P*\<0.05 was considered statistically significant.

RESULTS
=======

Baseline characteristics
------------------------

Total 1,189 patients (157 males and 1,032 females) were included in the present study. The baseline characteristics of patients are shown in [Table 1](#T1){ref-type="table"}. The mean age was 45.3±11.9 years and 640 patients (53.8%) were older than 45 years of age. The mean maximal tumor diameter was 2.1±1.2 cm. Extrathyroidal invasion and multifocality of the primary tumors were present in 789 patients (66.4%) and 466 (39.2%), respectively. Of the 1,189 patients, 762 patients (64.1%) had cervical lymph node (LN) metastases, 181 (15.2%) had lateral neck LN metastases (N1b), and 25 (2.1%) had distant metastases at the initial diagnosis.

The mean BMI was 24.1±3.2 kg/m^2^ for all patients, 24.9±3.0 kg/m^2^ for the males, and 23.5±3.3 kg/m^2^ for the females. Of the 1,189 patients, 384 (32.3%) were overweight (BMI, 25.0 to 29.9 kg/m^2^), and 55 (4.6%) were obese (BMI ≥30.0 kg/m^2^). The proportion of overweight and obese patients (BMI ≥25 kg/m^2^) was markedly higher in males than females (48.4% vs. 35.2%, *P*=0.001).

Associations of BMI quartile groups with clinicopathological features of PTC
----------------------------------------------------------------------------

The clinicopathological features of the PTCs were evaluated according to BMI quartile categories ([Table 1](#T1){ref-type="table"}). There were no significant associations for primary tumor size, extrathyroidal invasion, LN metastasis, or distant metastasis according to BMI quartiles. However, the mean age showed a significant increase across BMI quartiles (*P*\<0.001). Multifocality and advanced TNM stage (stage III or IV) showed significantly increasing trends with the increases in BMI quartiles (*P* for trend=0.015 and \<0.001, respectively).

In multivariate analyses, these associations of increased BMI with multifocality (OR, 1.11; 95% CI, 0.99 to 1.23; *P*=0.067) and advanced TNM stage (OR, 1.11; 95% CI, 0.99 to 1.23; *P*=0.769) were disappeared after adjusting for age and gender. The associations between clinico-pathological features of PTC and BMI quartiles were also evaluated according to gender ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). The females showed the same patterns as overall subjects, while the proportion of the males with maximal tumor diameters larger than 2 cm was associated with higher BMI quartile (*P* for trend=0.043). However, its association disappeared after adjusting for age (The data was not shown).

Recurrence-free survivals according to BMI quartiles
----------------------------------------------------

After the exclusion of patients with distant metastases at initial diagnosis (*n*=25), the recurrence-free survivals of the PTC patients were evaluated during median 8.4 years of the follow-up period. Total 160 of 1,164 patients (13.7%) experienced PTC recurrence during the follow-up. There were no significant differences in recurrence-free survivals across the BMI quartiles (log rank statistics=4.0, *df*=3, *P*=0.26) ([Fig. 1](#F1){ref-type="fig"}).

DISCUSSION
==========

The present study evaluated associations of the increases in BMI with clinicopathological features and recurrence free survivals in patients who underwent total thyroidectomy for PTCs. There were no significant relationships between increased BMI and clinicopathological features of PTC. Patients with PTCs that were less than 1 cm in size were excluded because papillary thyroid microcarcinoma has favorable prognoses which included a low rate of distant metastasis and a low risk of disease recurrence \[[@B21][@B22][@B23]\].

In this study, we applied gender-specific BMI quartiles to the data to evaluate possible associations between increased BMI and clinicopathological features of PTC. Gender is an important contributing factor to obesity, and a significant difference in the proportion of obese patients according to gender was observed in our study (males vs. females, 48.4% vs. 35.2%; *P*=0.001). Therefore, gender-specific BMI quartiles were calculated to adjust for the differences in BMI distribution between males and females.

In univariate analyses, an advanced TNM stage was significantly associated with increased BMI. However, this increase was also associated with older age. Age at the time of diagnosis was a major variable when assessing tumor staging based on the AJCC TNM staging system \[[@B19]\]. Therefore, age might be a confounding factor when assessing the impact of obesity in the TNM stage of PTC. In our multivariate analysis, the positive association between BMI and advanced TNM stage disappeared after adjusting for age and gender.

The World Health Organization defined obesity as BMI ≥30.0 kg/m^2^ \[[@B24]\]. Tresallet et al. \[[@B5]\] suggested that overweight or obese patients with PTC larger than 1 cm in size had an increased risk of developing loco-regional persistent or recurrent disease (OR, 3.8; *P*=0.03). Using Western standards, these authors categorized 14.5% of patients as obese (BMI ≥30.0 kg/m^2^) and 29.3% of patients as overweight (BMI, 25.0 to 29.9 kg/m^2^). However, only 55 of 1,189 patients (4.6%) in the present study had BMI ≥30.0 kg/m^2^. The Korean Endocrine Society defined obesity as BMI ≥25.0 kg/m^2^ \[[@B25]\]. Using this definition, approximately 36% of patients in the present study were categorized as the obese group. This difference in the prevalence of obesity between Western countries and Korea may explain the lack of associations between obesity and clinico-pathological features of PTC. Therefore, BMI quartiles were used for analyses in this study.

This retrospective study has several limitations. First, information such as waist to hip ratio, percentage of body fat, skin-fold thickness, and assessments of intra-abdominal fat were unavailable. Thus, the present study defined obesity based only on BMI. Similarly, other potential contributing factors including the history of diabetes mellitus, dyslipidemia, smoking, and physical activity could not be obtained. However, this study did include a large, homogenous, and well-defined population of subjects (*n*=1,189) with PTC equal to or greater than 1 cm in size. Moreover, the study subjects underwent total thyroidectomy and followed by same strategy at one institution for long term period. And, we applied gender-specific BMI quartiles.

In conclusion, the present study found that increased BMI was not associated with the clinical outcomes of patients with PTC, including their clinicopathological features and recurrence-free survivals.
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![Recurrence-free survivals across the body mass index (BMI) quartiles. There were no significant differences in recurrence-free survivals of papillary thyroid carcinoma patients across the BMI quartiles. The numbers of patients who remained no evidence of disease at each time point were described at the bottom.](enm-30-305-g001){#F1}

###### Baseline Characteristics of Study Subjects and Associations between Body Mass Index Quartiles and Clinicopathological Features of Papillary Thyroid Carcinoma

![](enm-30-305-i001)

  Characteristic                Total (*n*=1,189)   Quartile according to body mass index   *P* value^b^                             
  ----------------------------- ------------------- --------------------------------------- -------------- ------------ ------------ --------------
  Age, yr                       45.3±11.9           44.7±11.3                               38.4±11.8      48.2±10.1    49.7±11.2    \<0.001^c,d^
   \<45                         549 (46.2)          146 (50.3)                              205 (70.0)     96 (31.9)    102 (33.4)   \<0.001^d^
   ≥45                          640 (53.8)          144 (49.7)                              88 (30.0)      205 (68.1)   203 (66.6)   
  Gender                                                                                                                             
   Male                         157 (13.2)          39 (13.4)                               39 (13.3)      38 (12.6)    41 (13.4)    0.939
   Female                       1,032 (86.8)        251 (86.6)                              254 (86.7)     263 (87.4)   264 (86.6)   
  Maximal tumor diameter, cm    2.1±1.2             2.0±1.1                                 2.2±1.2        2.0±1.0      2.1±1.2      0.209^c^
   ≤2                           775 (65.2)          199 (68.6)                              178 (60.8)     201 (66.8)   197 (64.6)   0.633
   \>2                          414 (34.8)          91 (31.4)                               115 (39.2)     100 (33.2)   108 (35.4)   
  Extrathyroidal invasion                                                                                                            
   Absent                       400 (33.6)          92 (31.7)                               112 (38.2)     101 (33.6)   95 (31.1)    0.586
   Present                      789 (66.4)          198 (68.3)                              181 (61.8)     200 (66.4)   210 (68.9)   
  Mutifocal                     466 (39.2)          115 (39.7)                              85 (29.0)      128 (42.5)   138 (45.2)   0.015^d^
  Lymph node metastasis                                                                                                              
   pN0/Nx                       427 (35.9)          100 (34.5)                              92 (31.4)      121 (40.2)   114 (37.4)   0.330^e^
   pN1a                         581 (48.9)          145 (50.0)                              148 (50.5)     138 (45.8)   150 (49.2)   
   pN1b                         181 (15.2)          45 (15.5)                               53 (18.1)      42 (14.0)    41 (13.4)    
  Distant metastasis, present   25 (2.1)            6 (2.1)                                 11 (3.8)       5 (1.7)      3 (1.0)      0.145
  Staging according to TNM                                                                                                           
   I/II                         638 (53.7)          165 (56.9)                              217 (74.1)     129 (42.9)   127 (41.6)   \<0.001^d^
   III/IV                       551 (46.3)          125 (43.1)                              76 (25.9)      172 (57.1)   178 (58.4)   

Values are expressed as mean±SD or number (%).

TNM, tumor node metastasis.

^a^Quartiles for body mass index (kg/m^2^): Q1 19.4-23.0, Q2 23.1-24.9 , Q3 25.0-26.9, and Q4 27.0-38.2 for males and Q1 15.8-21.7, Q2 21.8-23.5, Q3 23.6-25.9, and Q4 26.0-37.1 for females; ^b^*P* values for trends across the body mass index quartiles were conducted using a Cochran-Armitage trend test, except nodal metastasis variable; ^c^*P* values by analysis of variance; ^d^Statistically significant; ^e^Nodal metastasis variable was analyzed by a chi-square test.

###### Associations between Body Mass Index Quartile and Clinicopathological Features for Females

![](enm-30-305-i002)

  Variable                      Total (*n*=1,032)   Quartile according to body mass index   *P* value^b^                             
  ----------------------------- ------------------- --------------------------------------- -------------- ------------ ------------ --------------
  Age, yr                       45.3±11.9           44.3±11.2                               37.6±11.3      48.3±10.0    50.7±10.7    \<0.001^c,d^
   \<45                         476 (46.1)          129 (51.4)                              187 (73.6)     79 (30.0)    81 (30.7)    \<0.001^d^
   ≥45                          556 (53.9)          122 (48.6)                              67 (26.4)      184 (70.0)   183 (69.3)   
  Maximal tumor diameter, cm    2.0±1.1             2.0±1.0                                 2.1±1.1        1.9±1.0      2.0±1.1      0.441^c^
   ≤2                           695 (67.3)          172 (68.5)                              160 (63.0)     185 (70.3)   178 (67.4)   0.751
   \>2                          337 (32.7)          79 (31.5)                               94 (37.0)      78 (29.7)    86 (32.6)    
  Extrathyroidal invasion                                                                                                            
   Absent                       345 (33.4)          78 (31.1)                               93 (36.6)      91 (34.6)    83 (31.4)    0.928
   Present                      687 (66.6)          173 (68.9)                              161 (63.4)     172 (65.4)   181 (68.6)   
  Mutifocal                     411 (39.8)          99 (39.4)                               75 (29.5)      113 (43.0)   124 (47.0)   0.008^d^
  Lymph node metastasis                                                                                                              
   pN0/Nx                       393 (38.1)          93 (37.1)                               83 (32.7)      113 (43.0)   104 (39.4)   0.210^e^
   pN1a                         502 (48.6)          126 (50.2)                              128 (50.4)     122 (46.4)   126 (47.7)   
   pN1b                         137 (13.3)          32 (12.7)                               43 (16.9)      28 (10.6)    34 (12.9)    
  Distant metastasis, present   20 (1.9)            5 (2.0)                                 9 (3.5)        4 (1.5)      2 (0.8)      0.131
  Staging according to TNM                                                                                                           
   I/II                         559 (54.2)          146 (58.2)                              196 (77.2)     111 (42.2)   106 (40.2)   \<0.001^d^
   III/IV                       473 (45.8)          105 (41.8)                              58 (22.8)      152 (57.8)   158 (59.8)   

Values are expressed as mean±SD or number (%).

TNM, tumor node metastasis.

^a^Quartiles for body mass index (kg/m^2^): Q1 15.8-21.7, Q2 21.8-23.5, Q3 23.6-25.9, and Q4 26.0-37.1 for females; ^b^*P* values for trends across the body mass index quartiles were conducted using a Cochran-Armitage trend test, except nodal metastasis variable; ^c^*P* values by analysis of variance; ^d^Statistically significant; ^e^Nodal metastasis variable was analyzed by a chi-square test.

###### Associations between Body Mass Index Quartiles and Clinicopathological Features for Males

![](enm-30-305-i003)

  Variable                      Total (*n*=157)   Quartile according to body mass index   *P* value^b^                           
  ----------------------------- ----------------- --------------------------------------- -------------- ----------- ----------- ----------
  Age, yr                       45.2±12.5         47.1±12.1                               43.0±14.1      47.6±11.1   43.5±12.1   0.234^c^
   \<45                         73 (46.5)         17 (43.6)                               18 (46.2)      17 (44.7)   21 (51.2)   0.538
   ≥45                          84 (53.5)         22 (56.4)                               21 (53.8)      21 (55.3)   20 (48.8)   
  Maximal tumor diameter, cm    2.5±1.5           2.1±1.6                                 2.7±1.8        2.6±1.1     2.8±1.6     0.200^c^
   ≤2                           80 (51.0)         27 (69.2)                               18 (46.2)      16 (42.1)   19 (46.3)   0.043^d^
   \>2                          77 (49.0)         12 (30.8)                               21 (53.8)      22 (57.9)   22 (53.7)   
  Extrathyroidal invasion                                                                                                        
   Absent                       55 (35.0)         14 (35.9)                               19 (48.7)      10 (26.3)   12 (29.3)   0.214
   Present                      102 (65.0)        25 (64.1)                               20 (51.3)      28 (73.7)   29 (70.7)   
  Mutifocal                     55 (35.0)         116 (41.0)                              10 (25.6)      15 (39.5)   14 (34.1)   0.838
  Lymph node metastasis                                                                                                          
   pN0/Nx                       34 (21.7)         7 (17.9)                                9 (23.1)       8 (21.1)    10 (24.4)   0.570^e^
   pN1a                         79 (50.3)         19 (48.7)                               20 (51.3)      16 (42.1)   24 (58.5)   
   pN1b                         44 (28.0)         13 (33.3)                               10 (25.6)      14 (36.8)   7 (17.1)    
  Distant metastasis, present   5 (3.2)           1 (2.6)                                 2 (5.1)        1 (2.6)     1 (2.4)     0.815
  Staging according to TNM                                                                                                       
   I/II                         79 (50.3)         19 (48.7)                               21 (53.8)      18 (47.4)   21 (51.2)   0.973
   III/IV                       78 (49.7)         20 (51.3)                               18 (46.2)      20 (52.6)   20 (48.8)   

Values are expressed as mean±SD or number (%).

TNM, tumor node metastasis.

^a^Quartiles for body mass index (kg/m^2^); Q1 19.4-23.0, Q2 23.1-24.9, Q3 25.0-26.9, and Q4 27.0-38.2 for males; ^b^*P* values for trends across the body mass index quartiles were conducted using a Cochran-Armitage trend test, except nodal metastasis variable; ^c^*P* values by analysis of variance; ^d^Statistically significant; ^e^Nodal metastasis variable was analyzed by a chi-square test.
